---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017917"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:04:55.772182+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Q3 net loss widens to $3.5M; begins Phase 1/1b for BP1002 in AML

## Summary
- Net loss $3.5M ($0.49/share) vs $2.1M ($0.29/share) in Q3 2021.
- R&D expense doubled to $2.4M on manufacturing costs and BP1001-A trial startup.
- Cash $13.7M at Sep 30, 2022, down from $23.8M at Dec 31, 2021; YTD ops burn $10.1M.
- First patient dosed in Phase 1/1b study of BP1002 for refractory/relapsed AML.
- Closed $2.0M registered direct offering of 800k shares at $2.50 each, with warrants.

## SEC filing metadata
- accession: 0001558370-22-017917
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/0001558370-22-017917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/bpth-20221115x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017917
- JSON: https://secwatch.observer/filing/0001558370-22-017917.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017917.txt

## Key facts
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported three months ended September 30, 2022 results: net income Net loss of $3.5 million, EPS $0.49 per share.
  - Period: three months ended September 30, 2022
  - Net income: Net loss of $3.5 million
  - EPS: $0.49 per share
  - Result: reported results
  source text: The Company reported a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022, compared to a net loss of $2.1 million, or $0.29 per share, for the three months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/0001558370-22-017917-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.